Yin Yuan, Ming Liang, Qin Yan, Tang Junhui, Liu Bingxin, Liu Yuhang, Jin Guoying, Jiang Lingzhen, Yao Surui, Qi Xiaowei, Huang Zhaohui
Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, China.
Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Oncogene. 2025 Sep 16. doi: 10.1038/s41388-025-03566-y.
Chemoresistance is not only related to tumor cells themselves, but also regulated by the interaction between cells in the tumor microenvironment (TME). However, the underlying mechanisms are not well understood. RAB22A, a member of the RAB family of small GTPases that was identified by our group previously as an oncogene in colorectal cancer (CRC). In this study, we demonstrated that elevated expression of RAB22A in CRC cells, particularly in chemoresistant CRC cells, is associated with increased exosome secretion and enhanced chemoresistance. Mechanistically, RAB22A augments exosome secretion by inhibiting the ubiquitination and degradation of pyruvate kinase type M2 (PKM2), then promoting the phosphorylation of synaptosome-associated protein 23 (SNAP-23). Furthermore, RAB22A not only directly promotes chemoresistance in CRC cells but also indirectly induces acquired drug resistance of other CRC cells in the TME by promoting the secretion of RAB22A-PKM2-rich exosomes, thereby triggering intercellular chemoresistance transmission. Together, we reveal an essential role of RAB22A-PKM2-SNAP-23 signaling cascade in exosome induction in chemoresistant CRC cells and intercellular chemoresistance transmission, highlighting that targeting the RAB22A/PKM2/pSNAP axis is a potential novel strategy to reverse chemoresistance, and suggest circulating exosomal RAB22A and PKM2 as markers to predict the efficacy of chemotherapy in CRC.
化疗耐药不仅与肿瘤细胞本身有关,还受肿瘤微环境(TME)中细胞间相互作用的调控。然而,其潜在机制尚不完全清楚。RAB22A是小GTP酶RAB家族的成员之一,我们团队先前已将其鉴定为结直肠癌(CRC)中的一种癌基因。在本研究中,我们证明CRC细胞中,尤其是化疗耐药的CRC细胞中RAB22A表达升高与外泌体分泌增加和化疗耐药增强有关。机制上,RAB22A通过抑制丙酮酸激酶M2型(PKM2)的泛素化和降解来增加外泌体分泌,进而促进突触小体相关蛋白23(SNAP-23)的磷酸化。此外,RAB22A不仅直接促进CRC细胞的化疗耐药,还通过促进富含RAB22A-PKM2的外泌体分泌,间接诱导TME中其他CRC细胞获得性耐药,从而触发细胞间化疗耐药传递。总之,我们揭示了RAB22A-PKM2-SNAP-23信号级联在化疗耐药CRC细胞外泌体诱导和细胞间化疗耐药传递中的重要作用,强调靶向RAB22A/PKM2/pSNAP轴是逆转化疗耐药的一种潜在新策略,并建议将循环外泌体RAB22A和PKM2作为预测CRC化疗疗效的标志物。